A large Finnish case-control study suggests that postmenopausal hormone therapy results in a 9-17% increase in the risk of Alzheimer’s disease. However, the small effect size, and likely confounding of use effect, does not provide strong evidence for a causal relationship.
Recommendations for menopausal hormone therapy were widely publicized and adopted following the original publication of the results of the Women’s Health Initiative and affected both initiation and continuation of estrogen therapy through at least 2013.
To inform clinical decision-making, investigators performed an analysis looking at the frequency of postmenopausal bleeding in endometrial cancers and the risk of endometrial cancer among women who have postmenopausal bleeding.
Postmenopausal hormone therapy may reduce the risk of developing age-related hyperkyphosis, commonly known as a “Dowager’s hump,” and the benefit from hormone therapy use in early menopause may provide long-term benefit.
The U.S. Preventive Services Task Force has issued a final recommendation statement and evidence summary upholding its earlier recommendation against use of hormone therapy for the primary prevention of chronic conditions in postmenopausal women.